We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
-2.54%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$49.4B
AUM Growth
-$1.83B
(-3.6%)
Cap. Flow
+$236M
Cap. Flow
% of AUM
0.48%
Top 10 Holdings %
Top 10 Hldgs %
23.11%
Holding
2,899
New
506
Increased
652
Reduced
806
Closed
772
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.93B |
| 2 |
Kenvue
KVUE
|
+$537M |
| 3 |
Humana
HUM
|
+$477M |
| 4 |
AbbVie
ABBV
|
+$441M |
| 5 |
Microsoft
MSFT
|
+$384M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$747M |
| 2 |
Apple
AAPL
|
+$565M |
| 3 |
ATVI
Activision Blizzard
ATVI
|
+$467M |
| 4 |
McKesson
MCK
|
+$347M |
| 5 |
Intel
INTC
|
+$300M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.79% |
| 2 | Healthcare | 17.06% |
| 3 | Consumer Discretionary | 12.96% |
| 4 | Consumer Staples | 7.45% |
| 5 | Financials | 6.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INZY
1651
DELISTED
Inozyme Pharma
INZY
| $570K | ﹤0.01% |
135,783
+7,876
| +6% | +$40.1K |
|
1652
Inter&Co
INTR
$2.45B
| $570K | ﹤0.01% |
142,480
-56,756
| -28% | -$218K |
|
|
EXE
1653
Expand Energy Corp
EXE
$21.7B
| $570K | ﹤0.01% |
6,607
-108,393
| -94% | -$9.2M |
|
1654
Universal Electronics
UEIC
$57.6M
| $568K | ﹤0.01% |
62,748
+40,330
| +180% | +$398K |
|
1655
Puma Biotechnology
PBYI
$407M
| $563K | ﹤0.01% |
214,213
-10,580
| -5% | -$36K |
|
1656
Duke Energy
DUK
$100B
| $561K | ﹤0.01% |
6,355
-252,504
| -98% | -$23.1M |
|
|
MOBVW
1657
CALL
DELISTED
Mobiv Acquisition Corp Warrant
MOBVW
| $560K | ﹤0.01% |
55,372
| – | – |
|
1658
CALL
Beneficient Warrant
BENFW
$185K
| $559K | ﹤0.01% |
215,853
| – | – |
|
1659
iShares Russell 1000 Growth ETF
IWF
$120B
| $559K | ﹤0.01% |
8,400
+5,052
| +151% | +$349K |
|
1660
Ameresco
AMRC
$1.12B
| $557K | ﹤0.01% |
14,451
-116,594
| -89% | -$5.64M |
|
1661
Stellus Capital Investment Corp
SCM
$204M
| $557K | ﹤0.01% |
40,950
-71,525
| -64% | -$1.02M |
|
1662
MediaAlpha
MAX
$734M
| $556K | ﹤0.01% |
67,364
-55,640
| -45% | -$497K |
|
|
ESTE
1663
DELISTED
Earthstone Energy Inc. Class A Common Stock
ESTE
| $556K | ﹤0.01% |
27,456
-823,025
| -97% | -$14.3M |
|
1664
Kimbell Royalty Partners
KRP
$1.45B
| $555K | ﹤0.01% |
+34,702
| New | +$526K |
|
1665
iShares US Telecommunications ETF
IYZ
$1.18B
| $555K | ﹤0.01% |
+26,060
| New | +$576K |
|
1666
Lands' End
LE
$375M
| $554K | ﹤0.01% |
74,230
-86,828
| -54% | -$738K |
|
1667
Mesa Laboratories
MLAB
$540M
| $554K | ﹤0.01% |
+5,276
| New | +$676K |
|
1668
Automatic Data Processing
ADP
$102B
| $553K | ﹤0.01% |
2,300
+377
| +20% | +$91.9K |
|
1669
United Therapeutics
UTHR
$26.3B
| $553K | ﹤0.01% |
+2,448
| New | +$564K |
|
1670
Regenxbio
RGNX
$622M
| $547K | ﹤0.01% |
+33,249
| New | +$603K |
|
1671
Iris Energy
IREN
$13B
| $545K | ﹤0.01% |
146,777
-22,061
| -13% | -$118K |
|
1672
Emergent Biosolutions
EBS
$378M
| $543K | ﹤0.01% |
159,780
-25,784
| -14% | -$143K |
|
|
YMAB
1673
DELISTED
Y-mAbs Therapeutics
YMAB
| $539K | ﹤0.01% |
98,931
-28,737
| -23% | -$167K |
|
|
AISPW
1674
CALL
Airship AI Holdings Warrants
AISPW
$15.6M
| $539K | ﹤0.01% |
48,965
-559,044
| -92% | -$122K |
|
1675
Pilgrim's Pride
PPC
$6.94B
| $538K | ﹤0.01% |
+23,551
| New | +$573K |
|
Similar funds
Marshall Wace's Q3 2023 Portfolio in Review
As of Q3 2023, Marshall Wace held 2,899 positions worth $49.4B, down 3.6% from $51.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Marshall Wace's Q3 2023 filing shows 506 new, 652 increased, 806 reduced and 772 closed positions. Its largest new stake was Humana: 1,014,185 shares worth $493M. The largest sale was Amazon, an estimated $747M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Marshall Wace's largest Q3 2023 buy was Humana: 1,014,185 shares worth $493M.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q3 2023, an estimated $1.93B increase.
- Marshall Wace's biggest Q3 2023 reduction was Amazon, cutting an estimated $747M.
- Marshall Wace fully exited Johnson & Johnson in Q3 2023, selling an estimated $284M.
- Marshall Wace's ten largest holdings make up 23% of its $49.4B portfolio in Q3 2023.
- Marshall Wace opened 506 new positions and closed 772 in Q3 2023.
- Marshall Wace's portfolio value fell 3.6% quarter-over-quarter to $49.4B.
Based on Marshall Wace's 13F filing for Q3 2023, filed 14 Nov 2023.